Abstract
Treatment of psoriasis is rapidly changing, and there have been dramatic additions such as topical vitamin D analogs and a topical retinoid to the therapeutic armamentarium in recent years. Even though drug therapy is often inadequate and serves only to abate the skin disorder, anthralin of the anthracenone antipsoriatics clears the rash totally. Of all antipsoriatic agents, anthralin has proven to be the most remarkably consistent and time-honored drug for treating the disease. However, anthralin therapy is accompanied by inflammation and staining of the nonaffected skin surrounding a psoriatic lesion. A large body of evidence has shown that the biochemical basis for its mechanism of action at the molecular level is related to its redox chemistry leading to the production of oxygen radicals. These can react with all classes of biological macromolecules and are involved in the principal cellular effects of the anthracenones. This article will focus on current strategies to minimize the potential of skin inflammation by anthralin and the underlying concepts of controlling and manipulating oxygen-radical generation which are essential for the rational design of novel anthracenones. Various studies have shown that by altering the structure of anthralin the in vitro profile can be markedly altered from an only moderate 5-lipoxygenase inhibitor to a more potent inhibitor of this enzyme, which may reflect improved activity against the inflammatory component of psoriasis while the antiproliferative activity is retained. The structural change is also accompanied by significantly diminished oxygen-radical generation and proinflammatory action on the skin. In particular, derivatives bearing a phenylacyl substituent in the critical 10-position of the anthracenone molecule have a favorable overall profile for achieving improved topical therapy of psoriasis.
Keywords: Anthracenone Antipsoriatics, Psoriasis, Streptococci, Stress, Endocrine factors, Beta blockers, Nonsteroidal antiinflammatory drugs, Angiotensin converting enzyme, Keratinocytes, T lymphocytes, Polymorphonuclear leukocytes, Makrophages, Endothelial cells, Ca binding protein psoriasin, Anthracenones, Epidermal growth factor, Endothelial leukocyte adhesion molecule 1, Interleukin, Lactate dehydrogenase, 5 Lipoxygenase, Platelet activating factor, Vascular cell adhesion molecule 1
Current Pharmaceutical Design
Title: Current Status and Recent Developments in Anthracenone Antipsoriatics
Volume: 6 Issue: 9
Author(s): Klaus Muller
Affiliation:
Keywords: Anthracenone Antipsoriatics, Psoriasis, Streptococci, Stress, Endocrine factors, Beta blockers, Nonsteroidal antiinflammatory drugs, Angiotensin converting enzyme, Keratinocytes, T lymphocytes, Polymorphonuclear leukocytes, Makrophages, Endothelial cells, Ca binding protein psoriasin, Anthracenones, Epidermal growth factor, Endothelial leukocyte adhesion molecule 1, Interleukin, Lactate dehydrogenase, 5 Lipoxygenase, Platelet activating factor, Vascular cell adhesion molecule 1
Abstract: Treatment of psoriasis is rapidly changing, and there have been dramatic additions such as topical vitamin D analogs and a topical retinoid to the therapeutic armamentarium in recent years. Even though drug therapy is often inadequate and serves only to abate the skin disorder, anthralin of the anthracenone antipsoriatics clears the rash totally. Of all antipsoriatic agents, anthralin has proven to be the most remarkably consistent and time-honored drug for treating the disease. However, anthralin therapy is accompanied by inflammation and staining of the nonaffected skin surrounding a psoriatic lesion. A large body of evidence has shown that the biochemical basis for its mechanism of action at the molecular level is related to its redox chemistry leading to the production of oxygen radicals. These can react with all classes of biological macromolecules and are involved in the principal cellular effects of the anthracenones. This article will focus on current strategies to minimize the potential of skin inflammation by anthralin and the underlying concepts of controlling and manipulating oxygen-radical generation which are essential for the rational design of novel anthracenones. Various studies have shown that by altering the structure of anthralin the in vitro profile can be markedly altered from an only moderate 5-lipoxygenase inhibitor to a more potent inhibitor of this enzyme, which may reflect improved activity against the inflammatory component of psoriasis while the antiproliferative activity is retained. The structural change is also accompanied by significantly diminished oxygen-radical generation and proinflammatory action on the skin. In particular, derivatives bearing a phenylacyl substituent in the critical 10-position of the anthracenone molecule have a favorable overall profile for achieving improved topical therapy of psoriasis.
Export Options
About this article
Cite this article as:
Muller Klaus, Current Status and Recent Developments in Anthracenone Antipsoriatics, Current Pharmaceutical Design 2000; 6 (9) . https://dx.doi.org/10.2174/1381612003400100
DOI https://dx.doi.org/10.2174/1381612003400100 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Regulation of Inflammation: A Review of Recent Advances in Anti- Inflammatory Strategies
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Molecular Biology of Nucleoside Transporters and their Distributions and Functions in the Brain
Current Topics in Medicinal Chemistry Molecular Pathways of Endothelial Cell Activation for (Targeted) Pharmacological Intervention of Chronic Inflammatory Diseases
Current Vascular Pharmacology Photopolymerizable Resins for 3D-Printing Solid-Cured Tissue Engineered Implants
Current Drug Targets Novel Plant Sterol and Stanol Derivatives with Beneficial Properties:Efficacy and Safety
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Exploring the Potential of NO-Independent Stimulators and Activators of Soluble Guanylate Cyclase for the Medical Treatment of Erectile Dysfunction
Current Pharmaceutical Design Anti-Selectin Therapy for the Treatment of Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Methylenetetrahydrofolate Reductase (MTHFR): A Novel Target for Cancer Therapy
Current Pharmaceutical Design Recent Advances in Design of Potential Quinoxaline Anti-Infectives
Current Medicinal Chemistry Novel Serine Protease Dipeptidyl Peptidase IV Inhibitor: Alogliptin
Mini-Reviews in Medicinal Chemistry The Different Strategies for Designing GPCR and Kinase Targeted Libraries
Combinatorial Chemistry & High Throughput Screening Natural Products As Antimitotic Agents
Current Topics in Medicinal Chemistry Evaluation of Assam Bora Rice Starch as Plasma Volume Expander by Polymer Analysis
Current Drug Delivery Aquaporin-1 and Sodium-Hydrogen Exchangers as Pharmacological Targets in Diabetic Atherosclerosis
Current Drug Targets ATP-Sensitive Potassium Channels
Current Pharmaceutical Design Platelets in Angiogenesis
Current Vascular Pharmacology Recent Trends in Targeted Anticancer Prodrug and Conjugate Design
Current Medicinal Chemistry 5'-Nucleotidases, Nucleosides and their Distribution in the Brain: Pathological and Therapeutic Implications
Current Medicinal Chemistry Alterations of Sex Differentiation in Males: From Candidate Genes to Diagnosis and Treatments
Current Pharmaceutical Design Soluble Epoxide Hydrolase, a Target with Multiple Opportunities for Cardiovascular Drug Discovery
Current Topics in Medicinal Chemistry